Why the study?
Does intravenous ferric carboxymaltose improve right ventricular function in symptomatic iron-deficient HFrEF patients on optimal medical therapy and CRT?
Population
75 symptomatic HFrEF patients with iron deficiency and reduced LVEF despite optimal medical therapy and CRT
Comparison
FCM vs placebo
Design
Pre-defined analysis of a double-blind 1:1 randomized controlled trial
Follow-up
3 months
Key result
Ferric carboxymaltose significantly improved right ventricular fractional area change compared to placebo (+4.1% vs -2.2%, p=0.002) at 3 months in HFrEF patients with iron deficiency.
Authors
Loading...
Supports ferric carboxymaltose for right ventricular remodeling in iron-deficient HFrEF; extends iron repletion benefits beyond left ventricular outcomes.
RCT (n=75)
Double-blind
1:1
Does intravenous ferric carboxymaltose improve right ventricular function in symptomatic iron-deficient HFrEF patients on optimal medical therapy and CRT?
Absolute Event Rate: 4.1% vs -2.2%
p-value: p=0.002
Intravenous ferric carboxymaltose significantly improves right ventricular function, structure, and contractile reserve in iron-deficient HFrEF patients already receiving optimal medical therapy and CRT.
Martens et al. (2022) conducted an RCT in Heart failure with reduced ejection fraction (HFrEF) and iron deficiency (n=75). Ferric carboxymaltose (FCM) vs. Placebo was evaluated on Change from baseline to 3-month follow-up in right ventricular fractional area change (RV FAC) (p=0.002). Ferric carboxymaltose significantly improved right ventricular fractional area change compared to placebo (+4.1% vs -2.2%, p=0.002) at 3 months in HFrEF patients with iron deficiency.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: